Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders
06 May 2022 - 7:00AM
Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical
company focused on innovative products for acute care settings,
today announced that it has adjourned its 2022 Annual Meeting of
Shareholders (the “Annual Meeting”), without any business being
conducted, due to lack of shareholder participation resulting in a
failure to reach required quorum. The Annual Meeting will reconvene
at 9:00 a.m. Eastern time on May 18, 2022 and will continue to be
held virtually at www.virtualshareholdermeeting.com/BXRX2022.
The record date for determining shareholders
eligible to vote at the Annual Meeting will remain the close of
business on March 29, 2022. Shareholders who have already submitted
a proxy do not need to vote again for the reconvened Annual
Meeting, as the proxies submitted will remain valid. Shareholders
who have already submitted proxies and want to change their vote
with respect to Proposals 1 and 2 can update their vote in the
manner set forth in the Proxy Statement. Your vote will be recorded
at the Annual Meeting in accordance with your most recently
submitted proxy.
Shareholders as of close of business on
the March 29, 2022 record date who have not voted are encouraged to
vote online at www.proxyvote.com or by telephone at 1-800-690-6903.
Shareholders needing assistance voting or have questions may
contact the Company’s proxy solicitation firm, Kingsdale Advisors,
at 1-855-476-6002 or contactus@kingsdaleadvisors.com.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused
on innovative products for acute care settings. ANJESO is the first
and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal
anti-inflammatory (NSAID) for the management of moderate to severe
pain. In addition to ANJESO, Baudax Bio has a pipeline of other
innovative pharmaceutical assets including two novel neuromuscular
blocking agents (NMBs) and a proprietary chemical reversal agent
specific to these NMBs. For more information, please
visit www.baudaxbio.com.
Forward Looking Statements
This press release contains forward-looking
statements that involve risks and uncertainties. Such
forward-looking statements reflect Baudax Bio’s expectations about
its future performance and opportunities that involve substantial
risks and uncertainties. When used herein, the words “anticipate,”
“believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,”
“intend,” and “expect,” and similar expressions, as they relate to
Baudax Bio or its management, are intended to identify such
forward-looking statements. These forward-looking statements are
based on information available to Baudax Bio as of the date of
publication on this internet site, and are subject to a number of
risks, uncertainties, and other factors that could cause Baudax
Bio’s performance to differ materially from those expressed in, or
implied by, these forward-looking statements. These forward-looking
statements should be considered together with the risks and
uncertainties that may affect Baudax Bio’s business and future
results included in Baudax Bio’s filings with the Securities and
Exchange Commission at www.sec.gov. These forward-looking
statements are based on information currently available to Baudax
Bio, and Baudax Bio assumes no obligation to update any
forward-looking statements except as required by applicable
law.
CONTACT:
Investor Relations Contact:Argot PartnersSam Martin / Kaela
Ilami(212) 600-1902baudaxbio@argotpartners.com
Media Contact:Argot PartnersDavid Rosen(212)
600-1902david.rosen@argotpartners.com
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From May 2023 to May 2024